Indication
Cardiogenic Shock
19 clinical trials
23 products
2 drugs
Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage CStatus: Not yet recruiting, Estimated PCD: 2024-07-01
Product
IstaroximeProduct
PlaceboClinical trial
Efficacy and Clinical Outcomes of Levosimendan in E-CPRStatus: Recruiting, Estimated PCD: 2023-04-30
Product
LevosimendanClinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Trial of a Topical Nitroglycerin Challenge to Detect Reversible Microcirculatory Dysfunction in Patients With Circulatory Shock.Status: Completed, Estimated PCD: 2022-02-01
Product
NitroglycerinClinical trial
A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation SupportStatus: Recruiting, Estimated PCD: 2026-07-30
Product
EnoxaparinProduct
ArgatrobanProduct
Unfractionated heparinClinical trial
Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock: a Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-03-30
Clinical trial
Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation : Impact on Organ Dysfunction in Patients Supported by Veino-arterial ECMO for Cardiogenic ShockStatus: Recruiting, Estimated PCD: 2024-02-09
Product
OxygenClinical trial
Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIXStatus: Completed, Estimated PCD: 2023-03-10
Product
Blood testsClinical trial
Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic ShockStatus: Recruiting, Estimated PCD: 2024-01-01
Product
CangrelorProduct
TicagrelorClinical trial
Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled StudyStatus: Completed, Estimated PCD: 2023-04-05
Product
Hydrocortisone + FlucortacProduct
VasopressorProduct
InotropeClinical trial
Myocardial Reserve in Advanced Heart Failure PatientsStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Product
Milrinone or DobutamineProduct
Dobutamine or MilrinoneClinical trial
Low-dose Dobutamine Infusion and Single-dose Tocilizumab in Acute Myocardial Infarction Patients With High Risk of Cardiogenic Shock Development - a 2x2 Multifactorial, Double-blinded, Randomized, Placebo Controlled TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Drug
TocilizumabProduct
DobutamineDrug
VarlilumabClinical trial
Beyond the Syndromic Approach in Critical Care: Identifying Biomarker-driven Subphenotypes of Circulatory ShockStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Product
anti-bodiesClinical trial
Use of mechaNical Left ventricuLar unlOading in Acute decompensateD Heart Failure Complicated by Cardiogenic Shock - the UNLOAD HF-CS Trial.Status: Not yet recruiting, Estimated PCD: 2027-10-01
Product
InotropesClinical trial
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. A Randomized Multicentric Open TrialStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Product
EmpagliflozinClinical trial
Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)Status: Completed, Estimated PCD: 2019-01-31
Product
Blood testClinical trial
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial InfarctionStatus: Recruiting, Estimated PCD: 2025-06-01
Product
NoradrenalineClinical trial
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock PatientsStatus: Recruiting, Estimated PCD: 2024-08-01